| No |
품목명 |
| 1 |
In vitro cytotoxicity test |
| 2 |
In vitro cytotoxicity test - Agar diffusion method |
| 3 |
In vitro cytotoxicity test - Filter diffusion method |
| 4 |
Intracutaneous reactivity test |
| 5 |
Skin irritation test |
| 6 |
Vaginal irritation test without Histopathology |
| 7 |
Skin sensitization test (GPMT method) |
| 8 |
Acute systemic toxicity test |
| 9 |
Material mediated pyrogen test |
| 10 |
Ocular irritation test |
| 11 |
Oral mucosa Irritation Test |
| 12 |
Subacute/Subchronic (14 days) Systemic toxicity test |
| 13 |
Subacute/Subchronic (28 days) Systemic toxicity test |
| 14 |
Subacute/Subchronic (90 days) Systemic toxicity test |
| 15 |
Subacute/Subchronic (90 days) Systemic Toxicity – Route of administration (Implantation) |
| 16 |
Chronic systemic toxicity (26 Week’s) |
| 17 |
Genotoxicity; Bacterial reverse mutation (Ames) test |
| 18 |
Genotoxicity; Invitro Micronucleus test |
| 19 |
Genotoxicity; In vivo micronucleus test |
| 20 |
Genotoxicity; Chromosomal aberration test |
| 21 |
Genotoxicity; Mouse Lymphoma Assay |
| 22 |
Bone (13 weeks) Implantation test |
| 23 |
Intramuscular (1 week) implantation Test - 7 days |
| 24 |
Intramuscular (4 week’s) implantation Test - 28 days |
| 25 |
Intramuscular (8 week’s) implantation Test - 60 days |
| 26 |
Intramuscular (13 week’s) implantation Test - 90 days |
| 27 |
Intramuscular (26 week’s) implantation Test - 180 days |
| 28 |
Subcutaneous (1 week) implantation Test - 7 days |
| 29 |
Subcutaneous (2 week) implantation Test - 14 days |
| 30 |
Subcutaneous (4 week) implantation Test - 28 days |
| 31 |
Subcutaneous (8 week) implantation Test - 60 days |
| 32 |
Subcutaneous (13 week’s) implantation Test - 90 days |
| 33 |
Subcutaneous (26 weeks) implantation Test - 180 days |
| 34 |
Hemolysis Test: ASTM Indirect Contact Method |
| 35 |
Hemolysis Test: ASTM Direct Contact Method |
| 36 |
Hemocompatibility : Coagulation: Determination of the Partial Thromboplastin Time (PTT) |
| 37 |
Hemocompatibility : Platelet Activation Test (PF4) |
| 38 |
Hemocompatibility : Complement Activation : 3 donors, Sc5b9 |
| 39 |
Hemocompatibility : Hematology : Platelet and Leukocyte Activation, 3 donors |
| 40 |
Biological Evaluation Plan |
| 41 |
Biological Safety Assessment report (Biological Evaluation Report), Toxicological Risk Assessment |